Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast

Annovis Bio, Inc.

5 June 2024 at 8:00 am·3-min read

MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap.

Investor Call Details:

Date and Time: June 11, 2024, 4:30pm ET.
Register Today: https://zoom.us/webinar/register/WN_Ev_1s7l2RUKmIQJNdko5iA

Topics to Be Covered:

Recent advancements in the development of Buntanetap.
Strategic plans for upcoming clinical trials.
Overview of the company’s progress and future direction.

Register Today: Investors and interested parties are encouraged to register for the webcast in advance. To register, please visit https://zoom.us/webinar/register/WN_Ev_1s7l2RUKmIQJNdko5iA and complete the registration form.

About Buntanetap: Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in AD, PD, and other neurodegenerative diseases.

About Annovis Bio Inc.: Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit Annovis Bio's website and follow us on LinkedIn and X.

Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the Company's plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including regarding patient enrollment, the effectiveness of Buntanetap and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety and tolerability of buntanetap. See also additional risk factors set forth in the Company's periodic filings with the SEC, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contacts

Annovis Bio, Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact

Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
‍IR@annovisbio.com
Investor Website

Fool.co.uk
Glencore and Vodafone slashed their dividends. Could this FTSE 250 stock yielding 10% be next?
This FTSE 250 stock currently offers a huge yield. But with the company struggling, Edward Sheldon believes the dividend payout isn't sustainable. The post Glencore and Vodafone slashed their dividends. Could this FTSE 250 stock yielding 10% be next? appeared first on The Motley Fool UK.
Fool.co.uk
This growth stock that Warren Buffett owns just hit 52-week lows. Should I buy?
Jon Smith flags up a high-profile US stock that the great Warren Buffett bought back in 2020 but which has nosedived over recent months. The post This growth stock that Warren Buffett owns just hit 52-week lows. Should I buy? appeared first on The Motley Fool UK.
The Telegraph
Questor: Investors aren’t happy with this company’s strategy, but should stay patient
It is fair to say that last week’s strategic update from Legal & General is going down like a rattlesnake in a lucky dip with investors, and as a result much of our (paper) capital gain is ebbing away.
Fool.co.uk
Is the Diageo share price becoming a joke?
The Diageo share price can't stop falling. But does a historically low valuation make this FTSE 100 stock an unmissable buy? Paul Summers takes a closer look. The post Is the Diageo share price becoming a joke? appeared first on The Motley Fool UK.
Evening Standard
Inflation set to hit Bank of England's 2% target, but MPC not expected to cut interest rates
Inflation is set to hit the Bank of England’s target figure for the first time since July 2021
Fool.co.uk
9.9% dividend yield! Is this FTSE 100 stock a brilliant bargain?
This leading British enterprise looks like a delicious deal for passive income, trading at a low multiple while offering a near-double-digit dividend yield! The post 9.9% dividend yield! Is this FTSE 100 stock a brilliant bargain? appeared first on The Motley Fool UK.
Manchester Evening News
Lloyds, Santander, Barclays make 'major' changes for millions of customers this month
Some of these changes will impact current account and credit card holders, while some mortgage customers could also be affected
Fool.co.uk
Investing £5 a day in this dividend giant can make me a £14,067 annual second income!
This FTSE 100 high-yield star can make me a major second income, supported by a strong business outlook and an apparently undervalued share price. The post Investing £5 a day in this dividend giant can make me a £14,067 annual second income! appeared first on The Motley Fool UK.
Fool.co.uk
The FTSE 100’s full of undervalued gems. Are these 2 UK stocks primed for a strong recovery?
Lots of FTSE 100 shares have hit new highs this year, but some are lagging behind. Considering them while they're cheap could deliver long-term returns. The post The FTSE 100’s full of undervalued gems. Are these 2 UK stocks primed for a strong recovery? appeared first on The Motley Fool UK.
CityAM
Bank of England to hold rates even as inflation looks set to fall to two per cent
The rate-setting Monetary Policy Committee (MPC) left the door open for a June cut at its last meeting in May, but since then a number of data releases have pointed to stubborn inflationary pressures.
Barrons.com
Nvidia Stock Slips. New Price Target Is Highest on Wall Street.
FEATURE Nvidia stock was trading down slightly Monday. The chip maker has been getting more price-target upgrades on Wall Street. Nvidia shares fell 0.6% at $131.07 on Monday. The stock closed up 1.
The Telegraph
‘We want to retire at 57 and sail the world on a yacht – are our pensions big enough?’
Many of us spent our days in lockdown dreaming of what we would do and where we would go if it ever lifted – and for some that vision did not include work.
Evening Standard
Never mind the politics. The Bank of England must cut interest rates now to save the economy
City Voices: Trying to show it is not biased during an election is just as political a decision for the Bank as a rate cut
Fool.co.uk
Could this be one of the FTSE 100’s best cheap dividend shares?
Looking for the best dividend growth shares to buy? Our writer Royston Wild thinks this FTSE 100 housebuilder might well be too cheap to ignore. The post Could this be one of the FTSE 100’s best cheap dividend shares? appeared first on The Motley Fool UK.
Fool.co.uk
Does a 43% price drop make this undervalued UK stalwart one of the best cheap shares to buy now?
After losing a third of its value of the past five years, this might be one of the most undervalued UK shares to buy right now. The post Does a 43% price drop make this undervalued UK stalwart one of the best cheap shares to buy now? appeared first on The Motley Fool UK.
Business Insider
Wall Street's biggest bear explains what needs to happen for the stock market to avoid a 23% correction
"We remain cautious here, expecting economic growth to weaken, equities to correct, and investors to find a better entry point," JPMorgan said.
The Telegraph
Raise capital gains tax to cover higher benefit bills, says IMF
Britain and other rich nations should raise taxes on capital gains to support a surge in benefits spending, the International Monetary Fund (IMF) has said.
The Telegraph
Le Pen victory will raise French debt to post-war high, warns Goldman Sachs
A victory for Marine Le Pen in France’s elections would trigger a surge in the national debt pile to a fresh post-war high, Goldman Sachs has warned.
Fool.co.uk
3 dividend shares I’ve bought for the next decade!
I think these UK dividend shares can amplify my long-term passive income, and could even be on track to becoming future Dividend Aristocrats! The post 3 dividend shares I’ve bought for the next decade! appeared first on The Motley Fool UK.
Fool.co.uk
At £4.76, is the Aviva share price a steal? Here’s what the charts say!
Aviva has outperformed the Footsie over the last year. But is there still value in its share price? This Fool reckons so. Here's why. The post At £4.76, is the Aviva share price a steal? Here’s what the charts say! appeared first on The Motley Fool UK.

FTSE 100

FTSE 250

AIM

GBP/EUR

GBP/USD

Bitcoin GBP

CMC Crypto 200

S&P 500

DOW

CRUDE OIL

GOLD FUTURES

NIKKEI 225

HANG SENG

DAX

CAC 40

What Labour and the Tories are offering pensioners in their manifestos

Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast

Latest stories

Glencore and Vodafone slashed their dividends. Could this FTSE 250 stock yielding 10% be next?

This growth stock that Warren Buffett owns just hit 52-week lows. Should I buy?

Questor: Investors aren’t happy with this company’s strategy, but should stay patient

Is the Diageo share price becoming a joke?

Inflation set to hit Bank of England's 2% target, but MPC not expected to cut interest rates

9.9% dividend yield! Is this FTSE 100 stock a brilliant bargain?

Lloyds, Santander, Barclays make 'major' changes for millions of customers this month

Investing £5 a day in this dividend giant can make me a £14,067 annual second income!

The FTSE 100’s full of undervalued gems. Are these 2 UK stocks primed for a strong recovery?

Bank of England to hold rates even as inflation looks set to fall to two per cent

Nvidia Stock Slips. New Price Target Is Highest on Wall Street.

‘We want to retire at 57 and sail the world on a yacht – are our pensions big enough?’

Never mind the politics. The Bank of England must cut interest rates now to save the economy

Could this be one of the FTSE 100’s best cheap dividend shares?

Does a 43% price drop make this undervalued UK stalwart one of the best cheap shares to buy now?

Wall Street's biggest bear explains what needs to happen for the stock market to avoid a 23% correction

Raise capital gains tax to cover higher benefit bills, says IMF

Le Pen victory will raise French debt to post-war high, warns Goldman Sachs

3 dividend shares I’ve bought for the next decade!

At £4.76, is the Aviva share price a steal? Here’s what the charts say!